AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer

Condition(s) studied

Study summary

The AFU has set itself the task of setting up a register of medical practices in order to define possible improvements in the therapeutic management and follow-up of NMIBC. In order to obtain representative data, all urologists who are members of the AFU may be invited to include their patients.

Eligibility

Primary outcome measure(s)

• Recurrence-Free Survival — 5 years
  New bladder cancer (Whether NMIBC or MIBC).
• Performance of urine tests (biomarkers) — 5 years
  To evaluate the diagnostic performance of urine tests (biomarkers) available in France, and providing a binary result (positive: probable presence of a tumor recurrence; negative: probable absence of a tumor recurrence) correlated to the result of the bladder endoscopy performed as part of the routine care for the follow-up of NMIBC: determination of the negative and positive predictive values of biomarkers.

Trial sites (44)

+ 4 more sites — see the full list on the official registry below.

Other trials for the same condition